Prostate cancer is a curable disease for many patients. In fact, for some men, it requires no treatment at all – but we at the Brady want to make sure we correctly and safely identify those men. For men who do need treatment, we want to address their cancer with few to no side effects.

In a recent study, Matoso and colleagues assessed the sensitivity of blue light cystoscopy, and compared the results with the final pathology diagnoses. They found blue light cystoscopy allows them to detect CIS that would have been under-diagnosed with the conventional white light cystoscopy.

“We saw a reduction in opioid prescribing by nearly 47 percent, a reduction in opioid use by nearly 27 percent, and increased disposal of leftover opioids by nearly 14 percent.”

They don’t happen often, but Brady urologists would like to prevent them altogether: blood clots in the legs or lungs after radical prostatectomy.

Carter, retiring as the Bernard L. Schwartz Distinguished Professor of Urologic Oncology, reflects on his 32 years at the Brady.

At many hospitals worldwide, Gleason scoring is still less accurate. Unfortunately, says Epstein, “today only a minority of published articles on prostate cancer group Gleason scores accurately."

“We found that three genes, ATM, BRCA2, and MSH2, were mutated at a significantly higher rate in high-grade cancers.”

Now, we are pleased to report, the results of the Baltimore ORIOLE multicenter trial are even better than radiation oncologist Phuoc Tran, M.D., Ph.D. hoped.

Lupold sees PDCD4 levels as a key “thermostat” for prostate cancer, whose presence or absence helps determine whether the cancer cells will die, or go on to become independent of hormonal control.

Why are African American men 1.5 times more likely to get prostate cancer, and more than twice as likely to die of it as men of European descent? Brady investigators have discovered critical, inherited genetic mutations in men of African descent.